Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06234423 · ClinicalTrials.gov registry record · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
A Phase 1 study of Ovarian Cancer and Solid Tumor, sponsored by OnCusp Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 263
- Enrollment target
- 15
- Study locations
NCT06234423 is a Phase 1 study of Ovarian Cancer and Solid Tumor that is actively recruiting participants, run by OnCusp Therapeutics. The registered enrollment target is 263 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (64% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT06234423, a Phase 1 study of Ovarian Cancer and Solid Tumor, is actively recruiting participants, sponsored by OnCusp Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 263 participants
- Enrollment target
- 15
- Study locations
Study Summary
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Conditions Studied
Interventions
- DRUG CUSP06
Study Locations (15)
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - Houston
- START San Antonio - San Antonio
Florida
- Mount Sinai Medical Center - Miami Beach
- Florida Cancer Specialists - Sarasota
New York
- NYU Cancer Institute Clinical Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Connecticut
- Yale University - New Haven
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- START Midwest - Grand Rapids
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2024-02-09 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06234423
The ClinicalTrials.gov registry entry for NCT06234423 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (64% lower). The listed sponsor is OnCusp Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which CUSP06 is the first listed.
NCT06234423 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Texas, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06234423 about?
NCT06234423 is a clinical study titled "A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors". This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
What is the current status of trial NCT06234423?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 263 participants. The study started on 2024-02-09. Estimated completion is 2027-10-31.
What conditions does trial NCT06234423 study?
This clinical trial studies the following conditions: Ovarian Cancer, Solid Tumor.
What interventions are being tested in trial NCT06234423?
The interventions under investigation include: CUSP06 (DRUG).
Who is sponsoring clinical trial NCT06234423?
This trial is sponsored by OnCusp Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06234423 being conducted?
This trial has 15 study locations across Colorado, Connecticut, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.